论文部分内容阅读
三阴乳腺癌(TNBC)是乳腺癌中一个特殊的类型,具有特殊的分子表达类型和生物学特性,内分泌治疗和曲妥珠单抗靶向治疗无效且无明确治疗靶点,复发早、进展快、生存期短、早期易发生远处转移等特点。此类型乳腺癌对常规放射、化学治疗不敏感,导致其预后较其他类型乳腺癌差。对TNBC靶向治疗的深入研究,有助于人们采取更有效的治疗手段来提高疗效。在实体瘤的恶性生长及转移中,肿瘤的新生血管生成起着至关重要的作用,针对新生血管生成靶向治疗的研究成为热点。MRI技术是诊断乳腺癌的最准确的影像学方法,有助于肿瘤诊断、治疗方案制定、治疗反应及预后评估,并能加深对其生物学行为的理解。现对TNBC抗血管生成靶向治疗进展及MRI影像学疗效评价进行综述。
Triple negative breast cancer (TNBC) is a special type of breast cancer that has special molecular expression patterns and biological characteristics. Endocrine therapy and trastuzumab targeted therapy are ineffective and have no definite therapeutic target. Early recurrence and progression Fast, short survival, distant metastasis prone to early characteristics. This type of breast cancer is not sensitive to conventional radiation and chemotherapy, resulting in a worse prognosis than other types of breast cancer. In-depth study of TNBC targeted therapy will help people to take more effective treatment to improve the curative effect. In the malignant growth and metastasis of solid tumors, tumor neovascularization plays a crucial role, and targeted therapy of neovascularization has become a hot spot. MRI is the most accurate imaging method for diagnosing breast cancer and contributes to tumor diagnosis, treatment planning, treatment response and prognosis assessment, as well as to the understanding of its biological behavior. The progress of anti-angiogenesis targeted therapy of TNBC and the evaluation of MRI imaging efficacy are reviewed.